TriangleNCT00261846 · OUTCOME
Cumulative Incidence of Progression/Death - Part 2
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Years 1, 2, 3, 4, and 5 (CP2L only)
What was measured
The cumulative incidence of on-treatment progression or death adjusting for the competing risk of treatment discontinuation without the event. Disease progression was determined by the investigator as the reason for treatment discontinuation and death was due to any cause within 30 days of last dose. Duration in months = (date of PD/death or last valid cytogenetic/hematologic assessment if censored - first dose date)/30.4. 95% confidence intervals were calculated using Gray's method. NA = not estimable. One year = 12 months.
Analysis population: All-treated population included all enrolled participants who received at least one dose of study medication.
Groups in this outcome
Bosutinib 500 mg, CP2L-CML IM-R (Part 2)
Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.
Bosutinib 500 mg, CP2L-CML IM-I (Part 2)
Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.
Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)
Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I, D and NI R/I or IM R/I and NI-I CML.
Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)
Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-R CML.
Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)
Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-I CML.
Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)
Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and NI-R CML.
Bosutinib 500 mg, AP-CML IM R/I (Part 2)
Bosutinib 500 mg was administered orally once-daily in participants with AP IM R/I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.
Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)
Bosutinib 500 mg was administered orally once-daily in participants with AP Multi-TKI: IM, D and/or NI R/I CML.
Bosutinib 500 mg, BP-CML IM R/I (Part 2)
Bosutinib 500 mg was administered orally once-daily in participants with BP IM R/I CML ; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.
Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)
Bosutinib 500 mg was administered orally once-daily in participants with BP Multi-TKI: IM, D and/or NI R/I CML.
Bosutinib 500 mg, Ph+ ALL (Part 2)
Bosutinib 500 mg was administered orally once-daily in participants with Ph+ ALL
| Group | Source count |
|---|---|
| Bosutinib 500 mg, CP2L-CML IM-R (Part 2) | 195 |
| Bosutinib 500 mg, CP2L-CML IM-I (Part 2) | 89 |
| Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2) | 5 |
| Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2) | 38 |
| Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2) | 50 |
| Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2) | 26 |
| Bosutinib 500 mg, AP-CML IM R/I (Part 2) | 49 |
| Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2) | 30 |
| Bosutinib 500 mg, BP-CML IM R/I (Part 2) | 36 |
| Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2) | 28 |
| Bosutinib 500 mg, Ph+ ALL (Part 2) | 24 |
Reported measurements
Year 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Bosutinib 500 mg, CP2L-CML IM-R (Part 2) | 10.8 | Not reported | 7.2 | 16.1 | Not reported |
| Bosutinib 500 mg, CP2L-CML IM-I (Part 2) | 4.5 | Not reported | 1.7 | 11.7 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2) | 20.0 | Not reported | 3.5 | 100.0 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2) | 23.7 | Not reported | 13.4 | 41.9 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2) | 12.0 | Not reported | 5.7 | 25.4 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2) | 23.1 | Not reported | 11.4 | 46.6 | Not reported |
| Bosutinib 500 mg, AP-CML IM R/I (Part 2) | 28.6 | Not reported | 18.4 | 44.5 | Not reported |
| Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2) | 20.0 | Not reported | 9.8 | 40.9 | Not reported |
| Bosutinib 500 mg, BP-CML IM R/I (Part 2) | 47.2 | Not reported | 33.4 | 66.7 | Not reported |
| Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2) | 71.4 | Not reported | 56.5 | 90.3 | Not reported |
| Bosutinib 500 mg, Ph+ ALL (Part 2) | 58.3 | Not reported | 41.6 | 81.8 | Not reported |
Year 2
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Bosutinib 500 mg, CP2L-CML IM-R (Part 2) | 19.0 | Not reported | 14.2 | 25.4 | Not reported |
| Bosutinib 500 mg, CP2L-CML IM-I (Part 2) | 6.7 | Not reported | 3.1 | 14.6 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2) | 40.0 | Not reported | 13.7 | 100.0 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2) | 23.7 | Not reported | 13.4 | 41.9 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2) | 14.0 | Not reported | 7.0 | 27.8 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2) | 30.8 | Not reported | 17.3 | 54.8 | Not reported |
| Bosutinib 500 mg, AP-CML IM R/I (Part 2) | 42.9 | Not reported | 31.0 | 59.2 | Not reported |
| Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2) | 23.3 | Not reported | 12.2 | 44.6 | Not reported |
| Bosutinib 500 mg, BP-CML IM R/I (Part 2) | 50.0 | Not reported | 36.1 | 69.3 | Not reported |
| Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2) | 71.4 | Not reported | 56.5 | 90.3 | Not reported |
| Bosutinib 500 mg, Ph+ ALL (Part 2) | 58.3 | Not reported | 41.6 | 81.8 | Not reported |
Year 3
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Bosutinib 500 mg, CP2L-CML IM-R (Part 2) | 22.1 | Not reported | 16.9 | 28.7 | Not reported |
| Bosutinib 500 mg, CP2L-CML IM-I (Part 2) | 9.0 | Not reported | 4.6 | 17.4 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2) | 40.0 | Not reported | 13.7 | 100.0 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2) | 23.7 | Not reported | 13.4 | 41.9 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2) | 16.0 | Not reported | 8.5 | 30.2 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2) | 34.6 | Not reported | 20.4 | 58.7 | Not reported |
| Bosutinib 500 mg, AP-CML IM R/I (Part 2) | 44.9 | Not reported | 32.9 | 61.2 | Not reported |
| Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2) | 26.7 | Not reported | 14.7 | 48.3 | Not reported |
| Bosutinib 500 mg, BP-CML IM R/I (Part 2) | 50.0 | Not reported | 36.1 | 69.3 | Not reported |
| Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2) | 75.0 | Not reported | 60.6 | 92.9 | Not reported |
| Bosutinib 500 mg, Ph+ ALL (Part 2) | 58.3 | Not reported | 41.6 | 81.8 | Not reported |
Year 4
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Bosutinib 500 mg, CP2L-CML IM-R (Part 2) | 22.6 | Not reported | 17.4 | 29.3 | Not reported |
| Bosutinib 500 mg, CP2L-CML IM-I (Part 2) | 9.0 | Not reported | 4.6 | 17.4 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2) | 40.0 | Not reported | 13.7 | 100.0 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2) | 23.7 | Not reported | 13.4 | 41.9 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2) | 16.0 | Not reported | 8.5 | 30.2 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2) | 34.6 | Not reported | 20.4 | 58.7 | Not reported |
| Bosutinib 500 mg, AP-CML IM R/I (Part 2) | 44.9 | Not reported | 32.9 | 61.2 | Not reported |
| Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2) | 26.7 | Not reported | 14.7 | 48.3 | Not reported |
| Bosutinib 500 mg, BP-CML IM R/I (Part 2) | 50.0 | Not reported | 36.1 | 69.3 | Not reported |
| Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2) | 75.0 | Not reported | 60.6 | 92.9 | Not reported |
| Bosutinib 500 mg, Ph+ ALL (Part 2) | 58.3 | Not reported | 41.6 | 81.8 | Not reported |
Year 5
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Bosutinib 500 mg, CP2L-CML IM-R (Part 2) | 23.1 | Not reported | 17.9 | 29.8 | Not reported |
| Bosutinib 500 mg, CP2L-CML IM-I (Part 2) | 10.1 | Not reported | 5.4 | 18.8 | Not reported |
| Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2) | NA | Not reported | NA | NA | In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4. |
| Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2) | NA | Not reported | NA | NA | In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4. |
| Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2) | NA | Not reported | NA | NA | In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4. |
| Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2) | NA | Not reported | NA | NA | In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4. |
| Bosutinib 500 mg, AP-CML IM R/I (Part 2) | NA | Not reported | NA | NA | In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4. |
| Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2) | NA | Not reported | NA | NA | In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4. |
| Bosutinib 500 mg, BP-CML IM R/I (Part 2) | NA | Not reported | NA | NA | In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4. |
| Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2) | NA | Not reported | NA | NA | In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4. |
| Bosutinib 500 mg, Ph+ ALL (Part 2) | NA | Not reported | NA | NA | In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4. |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 7.2
- upper Limit
- 16.1
- value
- 10.8
- group Id
- OG001
- lower Limit
- 1.7
- upper Limit
- 11.7
- value
- 4.5
- group Id
- OG002
- lower Limit
- 3.5
- upper Limit
- 100.0
- value
- 20.0
- group Id
- OG003
- lower Limit
- 13.4
- upper Limit
- 41.9
- value
- 23.7
- group Id
- OG004
- lower Limit
- 5.7
- upper Limit
- 25.4
- value
- 12.0
- group Id
- OG005
- lower Limit
- 11.4
- upper Limit
- 46.6
- value
- 23.1
- group Id
- OG006
- lower Limit
- 18.4
- upper Limit
- 44.5
- value
- 28.6
- group Id
- OG007
- lower Limit
- 9.8
- upper Limit
- 40.9
- value
- 20.0
- group Id
- OG008
- lower Limit
- 33.4
- upper Limit
- 66.7
- value
- 47.2
- group Id
- OG009
- lower Limit
- 56.5
- upper Limit
- 90.3
- value
- 71.4
- group Id
- OG010
- lower Limit
- 41.6
- upper Limit
- 81.8
- value
- 58.3
- title
- Year 1
- categories
- measurements
- group Id
- OG000
- lower Limit
- 14.2
- upper Limit
- 25.4
- value
- 19.0
- group Id
- OG001
- lower Limit
- 3.1
- upper Limit
- 14.6
- value
- 6.7
- group Id
- OG002
- lower Limit
- 13.7
- upper Limit
- 100.0
- value
- 40.0
- group Id
- OG003
- lower Limit
- 13.4
- upper Limit
- 41.9
- value
- 23.7
- group Id
- OG004
- lower Limit
- 7.0
- upper Limit
- 27.8
- value
- 14.0
- group Id
- OG005
- lower Limit
- 17.3
- upper Limit
- 54.8
- value
- 30.8
- group Id
- OG006
- lower Limit
- 31.0
- upper Limit
- 59.2
- value
- 42.9
- group Id
- OG007
- lower Limit
- 12.2
- upper Limit
- 44.6
- value
- 23.3
- group Id
- OG008
- lower Limit
- 36.1
- upper Limit
- 69.3
- value
- 50.0
- group Id
- OG009
- lower Limit
- 56.5
- upper Limit
- 90.3
- value
- 71.4
- group Id
- OG010
- lower Limit
- 41.6
- upper Limit
- 81.8
- value
- 58.3
- title
- Year 2
- categories
- measurements
- group Id
- OG000
- lower Limit
- 16.9
- upper Limit
- 28.7
- value
- 22.1
- group Id
- OG001
- lower Limit
- 4.6
- upper Limit
- 17.4
- value
- 9.0
- group Id
- OG002
- lower Limit
- 13.7
- upper Limit
- 100.0
- value
- 40.0
- group Id
- OG003
- lower Limit
- 13.4
- upper Limit
- 41.9
- value
- 23.7
- group Id
- OG004
- lower Limit
- 8.5
- upper Limit
- 30.2
- value
- 16.0
- group Id
- OG005
- lower Limit
- 20.4
- upper Limit
- 58.7
- value
- 34.6
- group Id
- OG006
- lower Limit
- 32.9
- upper Limit
- 61.2
- value
- 44.9
- group Id
- OG007
- lower Limit
- 14.7
- upper Limit
- 48.3
- value
- 26.7
- group Id
- OG008
- lower Limit
- 36.1
- upper Limit
- 69.3
- value
- 50.0
- group Id
- OG009
- lower Limit
- 60.6
- upper Limit
- 92.9
- value
- 75.0
- group Id
- OG010
- lower Limit
- 41.6
- upper Limit
- 81.8
- value
- 58.3
- title
- Year 3
- categories
- measurements
- group Id
- OG000
- lower Limit
- 17.4
- upper Limit
- 29.3
- value
- 22.6
- group Id
- OG001
- lower Limit
- 4.6
- upper Limit
- 17.4
- value
- 9.0
- group Id
- OG002
- lower Limit
- 13.7
- upper Limit
- 100.0
- value
- 40.0
- group Id
- OG003
- lower Limit
- 13.4
- upper Limit
- 41.9
- value
- 23.7
- group Id
- OG004
- lower Limit
- 8.5
- upper Limit
- 30.2
- value
- 16.0
- group Id
- OG005
- lower Limit
- 20.4
- upper Limit
- 58.7
- value
- 34.6
- group Id
- OG006
- lower Limit
- 32.9
- upper Limit
- 61.2
- value
- 44.9
- group Id
- OG007
- lower Limit
- 14.7
- upper Limit
- 48.3
- value
- 26.7
- group Id
- OG008
- lower Limit
- 36.1
- upper Limit
- 69.3
- value
- 50.0
- group Id
- OG009
- lower Limit
- 60.6
- upper Limit
- 92.9
- value
- 75.0
- group Id
- OG010
- lower Limit
- 41.6
- upper Limit
- 81.8
- value
- 58.3
- title
- Year 4
- categories
- measurements
- group Id
- OG000
- lower Limit
- 17.9
- upper Limit
- 29.8
- value
- 23.1
- group Id
- OG001
- lower Limit
- 5.4
- upper Limit
- 18.8
- value
- 10.1
- comment
- In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.
- group Id
- OG002
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.
- group Id
- OG003
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.
- group Id
- OG004
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.
- group Id
- OG005
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.
- group Id
- OG006
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.
- group Id
- OG007
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.
- group Id
- OG008
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.
- group Id
- OG009
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.
- group Id
- OG010
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- title
- Year 5
- denoms
- counts
- group Id
- OG000
- value
- 195
- group Id
- OG001
- value
- 89
- group Id
- OG002
- value
- 5
- group Id
- OG003
- value
- 38
- group Id
- OG004
- value
- 50
- group Id
- OG005
- value
- 26
- group Id
- OG006
- value
- 49
- group Id
- OG007
- value
- 30
- group Id
- OG008
- value
- 36
- group Id
- OG009
- value
- 28
- group Id
- OG010
- value
- 24
- units
- Participants
- description
- The cumulative incidence of on-treatment progression or death adjusting for the competing risk of treatment discontinuation without the event. Disease progression was determined by the investigator as the reason for treatment discontinuation and death was due to any cause within 30 days of last dose. Duration in months = (date of PD/death or last valid cytogenetic/hematologic assessment if censored - first dose date)/30.4. 95% confidence intervals were calculated using Gray's method. NA = not estimable. One year = 12 months.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.
- id
- OG000
- title
- Bosutinib 500 mg, CP2L-CML IM-R (Part 2)
- description
- Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.
- id
- OG001
- title
- Bosutinib 500 mg, CP2L-CML IM-I (Part 2)
- description
- Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I, D and NI R/I or IM R/I and NI-I CML.
- id
- OG002
- title
- Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)
- description
- Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-R CML.
- id
- OG003
- title
- Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)
- description
- Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-I CML.
- id
- OG004
- title
- Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)
- description
- Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and NI-R CML.
- id
- OG005
- title
- Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)
- description
- Bosutinib 500 mg was administered orally once-daily in participants with AP IM R/I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.
- id
- OG006
- title
- Bosutinib 500 mg, AP-CML IM R/I (Part 2)
- description
- Bosutinib 500 mg was administered orally once-daily in participants with AP Multi-TKI: IM, D and/or NI R/I CML.
- id
- OG007
- title
- Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)
- description
- Bosutinib 500 mg was administered orally once-daily in participants with BP IM R/I CML ; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.
- id
- OG008
- title
- Bosutinib 500 mg, BP-CML IM R/I (Part 2)
- description
- Bosutinib 500 mg was administered orally once-daily in participants with BP Multi-TKI: IM, D and/or NI R/I CML.
- id
- OG009
- title
- Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)
- description
- Bosutinib 500 mg was administered orally once-daily in participants with Ph+ ALL
- id
- OG010
- title
- Bosutinib 500 mg, Ph+ ALL (Part 2)
- param Type
- NUMBER
- population Description
- All-treated population included all enrolled participants who received at least one dose of study medication.
- reporting Status
- POSTED
- time Frame
- Years 1, 2, 3, 4, and 5 (CP2L only)
- title
- Cumulative Incidence of Progression/Death - Part 2
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice